Background: The STICH trial (Surgical Treatment for Ischemic Heart Failure) demonstrated a
survival benefit of coronary artery bypass grafting in patients with ischemic cardiomyopathy …

Abstract The Parachute®(Cardiokinetix, Inc., Menlo Park, California) is a catheter-based
device intended to reverse left ventricular (LV) remodeling after antero-apical myocardial …

• Drug therapies focused on blockade of key activated neurohormonal systems are well
established in systolic heart failure. First-line pharmacotherapy consists of angiotensin …

Injection of Algisyl-LVR, a treatment under clinical development, is intended to treat patients
with dilated cardiomyopathy. This treatment was recently used for the first time in patients …

The insight that decreases in left ventricular (LV) volume and mass occur secondary to the
recovery of the myocardium at the cellular and molecular level has engendered a wider …

Ventricular aneurysm represents a rare complication of transmural acute myocardial
infarction, although other cardiac, congenital, or metabolic diseases may also predispose to …

Objective The role of surgical ventricular reconstruction (SVR) in patients with ischemic
cardiomyopathy is controversial. Observational series and the Surgical Treatment of …

Postinfarction left ventricular (LV) remodeling can result in chronic heart failure and
functional impairment. Although pharmacological strategies for established heart failure can …

An increase in left ventricular volume after a myocardial infarction is a key component of the
adverse remodelling process leading to chamber dysfunction, heart failure and an …

Background: Blinding minimizes measurement bias, particularly when the outcome being
assessed is patient-reported, since psychological measures of well-being and symptoms are …